Taken together, we show that intratumoral stimulation of RIG-I with its synthetic ligand 3pRNA in combination with the clinically relevant BRAF/MEK double inhibition outperforms the therapeutic effect of the individual therapies against BRAF-mutated melanoma in vivo. Here, RIGI is linked to melanoma.